Objectives: To study the effectiveness and safety of ledipasvir-sofosbuvir plus ribavirin treatment in Yemeni patient with HCV infection. Design: Prospective study of sixty-five Yemeni patients confirmed with HCV infection during the period from January 2017 to April 2018. Setting: Gastrointestinal and liver diseases specialized center in Ibb city, Yemen. Subjects: Patients with proved HCV infection by PCR. Results: We collected 65 cases with HCV infection. They were 19 (29.2%) males and 46 (70.8) females with age ranged between 18 years and 70 years and the mean age was 47.98 ± 11.90 years. sixteen (24.6%) of them had compensated liver cirrhosis and the remainder were non-cirrhotic healthy individual. The early virological response reported in 100% of cases while the sustained virological response (SVR) reported in 90.8%. The reported side effects of our patients were fatigue in (24.6%), abdominal pain in (13.8%), diarrhea in (10.8%), insomnia in (9.2%), headache in (7.7%), and nausea/vomiting in (7.7%). Conclusion: The Sofosbuvir-ledipasvir plus Ribavirin treatment was highly effective and safe for the treatment of hepatitis C patients in Yemen.
Cite this paper
Kassim, A. , Alathwary, R. and Al-hogami, T. (2019). Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin. Open Access Library Journal, 6, e5507. doi: http://dx.doi.org/10.4236/oalib.1105507.
James, S.D., Anna, S.F.L., Guadalupe, G.T. and Massimo, P. (2018) Sherlock’s Diseases of the Liver and Biliary System. 13th Edition, Vol. 1, John Wiley & Sons Ltd., Oxford, 436-459.
World Health Organization (2017) Global Hepatitis Report 2017. http://apps.who.int/iris/bitstream/handle/10665/ 255016/9789241565455-eng.pdf;jsessionid=E2D 0796013167FC7FFA0295C58EF490D?sequence=1
The Global Burden of Hepatitis C Working Group (2004) Global Burden of Disease (GBD) for Hepatitis C. The Journal of Clinical Pharmacology, 44, 20-29. https://doi.org/10.1177/0091270003258669
Mohd Hanafiah, K., Groeger, J., Flaxman, A.D. and Wiersma, S.T. (2013) Global Epidemiology of Hepatitis C Virus Infection: New Estimates of Age-Specific Antibody to HCV Seroprevalence. Hepatology, 57, 1333-1342. https://doi.org/10.1002/hep.26141
Petruzziello, A., Marigliano, S., Lo-quercio, G., Cozzolino, A. and Cacciapuoti, C. (2016) Global Epidemiology of Hepatitis C Virus Infection: An Up-Date of the Distribution and Circulation of Hepatitis C Virus Genotypes. World Journal of Gastroenterology, 22, 7824-7840. https://doi.org/10.3748/wjg.v22.i34.7824
Lavanchy, D. (2011) Evolving Epi-demiology of Hepatitis C Virus. Clinical Microbiology and Infection: The Official Publica-tion of the European Society of Clinical Microbiology and Infectious Diseases, 17, 107-115. https://doi.org/10.1111/j.1469-0691.2010.03432.x
Dennis, L.K., Stephen, L.H., Larry, J., Anthony, S.F., Dan, L.L. and Joseph, L. (2015) Harrison’s Principle of Internal Medicine. 19th Edition, Vol. 2, McGraw-Hill Education, New York, 2041-2052.
Thursz, M. and Fontanet, A. (2014) HCV Transmission in Industrialized Countries and Re-source-Constrained Areas. Nature Reviews Gastroenterology & Hepatology, 11, 28-35. https://doi.org/10.1038/nrgastro.2013.179
Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.S., Muljono, D.H., et al. (2017) Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modeling Study. The Lancet Gastroenterology & Hepatology, 2, 161-176. https://doi.org/10.1016/S2468-1253(16)30181-9
Al-Shamahy, H.A. and Abdu, S.S.A. (2013) Genotyping of Hepatitis C Virus (HCV) in Infected Patients from Yemen. European Journal of Basic Medical Science, 3, 78-82.
Zoulim, F., Liang, T.J., Gerbes, A.L., et al. (2015) Hepatitis C Virus Treatment in the Real World: Optimizing Treatment and Access to Therapies. Gut, 64, 1824-1833. https://doi.org/10.1136/gutjnl-2015-310421
Cheng, G., Tian, Y., Doehle, B., et al. (2016) In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. Antimicrobial Agents and Chemotherapy, 60, 1847-1853. https://doi.org/10.1128/AAC.02524-15
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. and Razavi, H. (2014) Global Epidemiology and Genotype Distribution of the Hepatitis C Virus Infection. Journal of Hepatology, 61, S45-S57. https://doi.org/10.1016/j.jhep.2014.07.027
Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., et al. (2015) All-Oral 12-Week Treatment with Daclatasvir plus Sofosbuvir in Patients with Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study. Hepatology, 61, 1127-1135. https://doi.org/10.1002/hep.27726
Hosny, S., Abdel, R.Z., Eman, M., Zienab, Z., Hend, S., Sherin, A.A. and Mervat, A.A. (2016) Sofosbuvir plus Daclatasvir with Fixed versus Weight Adjusted Dose of Ribavirin for Treatment of HCV, Genotype 4 among Egyptian Patients. EC Gastroenterology and Digestive System, 1, 143-153.
European Association for the Study of the Liver (2018) EASL Recom-mendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 69, 461-511. https://doi.org/10.1016/j.jhep.2018.03.026
Koff, R.S. (2014) Review Article: The Efficacy and Safety of Sofosbuvir, a Novel, Oral Nucleotide NS5B Polymer-ase Inhibitor, in the Treatment of Chronic Hepatitis C Virus infection. Alimentary Pharmacology & Therapeutics, 39, 478-487. https://doi.org/10.1016/j.jhep.2016.09.001
Basu, P., et al. (2015) Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir Combination Therapy in the Management of Acute Hepatitis C: A Randomized Open Label Prospective Clinical Pilot Study. SLAM C Study. AASLD 2015, San Francisco, 13-17 November 2015, 1-20.
Rajesh, N.G. and Sadiq, K.A. (2012) Seroprevalence and Risk Factors for Hepatitis C Virus Infection among General Population in Central Region of Yemen. Hepatitis Research and Treatment, 2012, Article ID: 689726. https://doi.org/10.1155/2012/689726
Ali, A., Ahmad, H., Ali, I., Khan, S., Zaidi, G. and Idrees, M. (2010) Prevalence of Active Hepatitis C Virus Infection in District Mansehra Pakistan. Virology Journal, 7, 334. https://doi.org/10.1186/1743-422X-7-334
Chen, S.L. and Morgan, T.R. (2006) The Natural History of Hepatitis C Virus, (HCV) Infection. International Journal Medical Science, 3, 47-52. https://doi.org/10.7150/ijms.3.47
Feld, J.J., Alnoor, R., Stephen, D.S., et al. (2017) Ledipasvir-Sofosbuvir plus Ribavirin in Treatment-Naive Patients with Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clinical Infectious Diseases, 65, 13-19. https://doi.org/10.1093/cid/cix289
Zubia, J., Yasir, W., Maryam, M. and Asghar, A.D. (2018) Effect of Sofosbuvir plus Ribavirin Therapy on Hepatitis C Patients in Pakistan: A Retrospective Study. Peer J, 6, e4853.
Hend, I.S., Karim, A., Sherif, R., Eman, M. and Gamal, E. (2018) Generic Sofosbuvir/Ledipasvir for Treatment of Na?ve, Non-Cirrhotic, Easy to Treat Patients with Chronic Hepatitis C Genotype 4: 8 vs. 12 Weeks of Treatment. Hepatitis Monthly, 18, e78777. https://doi.org/10.5812/hepatmon.78777
Shiha, G., Esmat, G., Hassany, M., Soliman, R., et al. (2019) Ledipasvir/Sofosbuvir with or without Ribavirin for 8 or 12 Weeks for the Treatment of HCV Genotype 4 Infection: Results from a Randomised Phase III Study in Egypt. Gut, 68, 721-728. https://doi.org/10.1136/gutjnl-2017-315906
Waheed, Y. (2015) Effect of Interferon plus Ribavirin Therapy on Hepatitis C Virus Genotype 3 Patients from Pakistan: Treatment Response, Side Effects and Future Prospective. Asian Pacific Journal of Tropical Medicine, 8, 85-89. https://doi.org/10.1016/S1995-7645(14)60193-0